Release Date: October 23, 2025
Expiration Date: October 23, 2026
Activity Overview
Prostate cancer remains a major clinical challenge, particularly in its advanced stage, when treatment decisions are increasingly complex. In this online, on-demand virtual symposium, renowned experts in prostate cancer participated in case discussions to address key decision points in integrating PSMA imaging and targeted therapies to improve patient outcomes.
This educational activity is an archive of a live symposium held on September 27, 2025.
Target Audience
ASTRO congress attendees, including an audience of radiation oncologists, medical oncologists, advanced practice providers, nurses, and pharmacists involved in the diagnosis and management of patients with prostate cancer
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the diagnostic and prognostic significance of PSMA PET/CT in prostate cancer, and interpret imaging findings to guide radiotherapy planning and clinical decision-making
- Assess recent clinical evidence for PSMA-targeted radioligand therapies, and define the role of radiation oncology in their delivery, monitoring, and coordination
- Design patient-centered strategies for incorporating PSMA-directed radioligand therapy into care pathways, including sequencing and coordination with other specialties
- Identify institutional and logistical barriers to radioligand therapy delivery, and propose solutions to expand access
Ana Kiess, MD, PhD
Associate Professor of Radiation Oncology
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: AstraZeneca, Novartis; Grant/Research Funding: Bayer, Lantheus, Novartis
Erin Grady, MD, CCD, FACNM, FSNMMI
Nuclear Medicine and Molecular Imaging Interim Division Chief
Associate Chair of Education and Diversity, Equity & Inclusion
Clinical Professor, Department of Radiology
Stanford University
Palo Alto, CA
Disclosures: Erin Grady, MD, CCD, FACNM, FSNMMI, has no relevant financial relationships with ineligible companies.
Himanshu Nagar, MD, MS
Director of Genitourinary Cancers
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: Boston Scientific, Elekta; Grant/Research Funding: AngioDynamics, Elekta, Lantheus, Teleflex
Scott T. Tagawa, MD, MS, FASCO, FACP
Professor of Medicine & Urology
Weill Cornell Medicine
Meyer Cancer Center New York, NY
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: AbbVie, Abdera, AIkido Pharma, Amgen, Bayer AG, Biohaven, Blue Earth Diagnostics, Boston Scientific, Clarity Pharmaceuticals, Clovis Oncology, Convergent Therapeutics, Daiichi Sankyo, Eisai Co, EMD Serono, Endocyte, General Electric, Genentech, Genomic Health, Immunomedics, Janssen, Karyopharm Therapeutics, Lantheus, Medivation/Astellas Pharma, Merck, Myovant Sciences, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seagen, Telix Pharmaceuticals, Tolmar, TransThera; Grant/Research Funding: AbbVie, AIQ, Ambrx, Ambrx Biopharma, Amgen, Astellas Pharma, AstraZeneca, Bayer AG, Bristol Myers Squibb, Clarity, Clovis Oncology, Endocyte, Gilead Sciences, Immunomedics, Janux, Janssen, Karyopharm Therapeutics, Medivation, Merck, Novartis, POINT Biopharma, Sanofi, Seagen, Telix; Royalty or Patent Benefits: Convergent, Gilead; Ownership interests in privately held companies: Convergent
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here